MIRA — MIRA Pharmaceuticals, Inc.
Is MIRA overbought or oversold? Here is the current MarketMoodz read.
MIRA Pharmaceuticals, Inc. (MIRA) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $0.63. The rating moved from Overbought to Neutral on November 14, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$0.63
- Last changeMoved from Overbought to Neutral on November 14, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
AI analysis
MIRA Pharmaceuticals, Inc. (MIRA) is a small, low‑visibility biopharma where limited public filings and minimal social/research attention make financial runway and program status hard to assess. Current market conditions favor large‑cap pharma and defensive healthcare exposure, reducing likely near‑term demand for speculative micro‑caps. Industry trends toward convertible financings increase dilution risk for mid‑cap and smaller issuers; absent clear near‑term positive clinical or partnership catalysts, downside from financing, poor liquidity, or negative binary outcomes is the primary near‑term scenario. Upside is possible if a clinical readout, regulatory decision, or strategic deal materializes, but these are binary and high impact.
Key factors
- Micro‑cap biopharma with limited public disclosure and no recent EDGAR filing context available, reducing visibility into financial runway.
- Sector flows favor large‑cap pharma and defensive healthcare, which can divert investor capital away from small speculative issuers.
- Industry trend of convertible‑debt financings in mid‑cap biotech increases likelihood of dilution and hedging pressure for similarly sized issuers.
- Low social/research signal and absent analyst coverage imply limited retail/institutional interest and shallow liquidity.
- Potential upside catalysts exist (clinical readouts, regulatory decisions, partnership or M&A interest) but are binary and high‑impact.
Risks
- High dilution risk from near‑term financing or convertible instruments that can greatly depress equity value.
- Binary clinical or regulatory outcomes that could cause steep share moves in either direction.
- Very low liquidity and trading volume, increasing price volatility and execution risk for holders.
- Lack of recent financial disclosures increases uncertainty about cash runway and operating burn.
- Competitive dynamics and sector rotation to larger, more established pharma may limit capital availability and strategic options.
See today's live rating, score and targets
Members see the live hourly rating for MIRA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.